4 results about "Factor Xa Inhibitor" patented technology

Providing a method for testing the efficacy of andexanet. [Solution] This disclosure relates to a kit and method for measuring the potency of an andexanet sample in neutralizing a factor Xa inhibitor and restoring the activity of wild-type factor Xa. This disclosure provides a method for determining the activity of an andexanet sample, comprising: mixing a test sample containing an andexanet with a mixture containing human factor Xa (HFXa) and a direct factor Xa (fXa) inhibitor, wherein the molar ratio of FXa to Xa inhibitor is 0.2:1 to 0.3:1; adding a chromogenic fXa substrate to the mixture, wherein the chromogenic fXa substrate can release a chromophore upon reaction with HFXa; detecting the amount of chromophore released; and calculating the activity of the andexanet sample in releasing HFXa from a direct fXa inhibitor from the amount of chromophore released.

A pharmaceutical composition comprising glutathione disulfide or pharmaceutically acceptable organic or inorganic salts thereof and glutathione disulfide S-oxide of the structure (I) or pharmaceutically acceptable organic or inorganic salts thereof for eliminating dose-related toxicity of pharmacologically active compounds and enhancing therapeutic activity of pharmacologically active compounds in the treatment of infectious and non-infectious diseases. Typically, the composition contains 0.01-10% of glutathione disulfide S-oxide by weight of the total composition, in addition to a metal (Me) in the form of a complexing compound containing Me-S-glutathione bond, said metal being selected from platinum group elements, typically platinum. The amount of d-metal complexing compound administered to a patient can be 10 ‑3 to 10 ‑15 mol / kg of body weight. The composition can be used in combination with pharmacologically active compounds, which are anticoagulants, factor Xa inhibitors, antibacterial or antiviral agents, to increase their therapeutic activity and eliminate dose-related toxicity.

This invention discloses an isolated anti-FXI and / or anti-FXIa antibody or its antigen-binding fragment, which specifically binds to human FXI or FXIa, and provides a drug targeting FXI that effectively prevents or treats thrombosis with minimal side effects to meet medical needs. Because currently approved anticoagulants interfere with hemostasis, leading to an increased risk of bleeding, there is a significant unmet medical need for safer anticoagulants. Although thrombosis can be treated or prevented with anticoagulants (e.g., heparin, warfarin, aspirin, or factor Xa inhibitors), these treatments have significant adverse effects. Genetic and pharmacological evidence in humans and animals suggests that lowering coagulation factor XI (FXI) can successfully prevent and manage thrombosis with minimal bleeding.